First Eagle Investment Management LLC bought a new position in shares of MiMedx Group, Inc (NASDAQ:MDXG – Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 794,607 shares of the company’s stock, valued at approximately $3,703,000. First Eagle Investment Management LLC owned 0.54% of MiMedx Group at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. BlackRock Inc. bought a new position in MiMedx Group during the 2nd quarter worth approximately $46,795,000. Nantahala Capital Management LLC acquired a new position in MiMedx Group during the second quarter valued at approximately $18,355,075. Paradigm Capital Management Inc. NY bought a new stake in MiMedx Group in the second quarter valued at approximately $15,681,000. Punch & Associates Investment Management Inc. bought a new stake in MiMedx Group in the second quarter valued at approximately $7,924,000. Finally, Cannell Capital LLC bought a new stake in MiMedx Group in the second quarter valued at approximately $7,201,179. 79.15% of the stock is owned by institutional investors.
Analyst Ratings Changes
MDXG has been the topic of a number of recent analyst reports. Raymond James Financial set a $8.00 price target on shares of MiMedx Group in a research report on Monday, August 17th. Cantor Fitzgerald restated an “overweight” rating and issued a $8.00 price objective on shares of MiMedx Group in a research report on Tuesday. Weiss Ratings downgraded MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, October 29th. Seaport Research Partners lowered MiMedx Group to a “neutral” rating in a report on Monday, August 17th. Finally, Wall Street Zen lowered MiMedx Group from a “hold” rating to a “sell” rating in a report on Saturday. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $8.14.
Read Our Latest Stock Analysis on MiMedx Group
MiMedx Group Stock Performance
Shares of MDXG stock opened at $3.06 on Friday. The company has a market capitalization of $445.82 million, a P/E ratio of -23.50 and a beta of 1.17. The company’s 50 day moving average price is $4.11 and its two-hundred day moving average price is $4.13. MiMedx Group, Inc has a 52 week low of $3.03 and a 52 week high of $7.45.
MiMedx Group (NASDAQ:MDXG – Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The company reported ($0.01) earnings per share for the quarter. MiMedx Group had a negative net margin of 6.32% and a positive return on equity of 2.39%. The company had revenue of $62.28 million during the quarter, compared to analyst estimates of $68.56 million. Analysts forecast that MiMedx Group, Inc will post -0.08 earnings per share for the current year.
MiMedx Group Company Profile
MiMedx Group is a healthcare company that develops and markets biologic products made from donated human placental tissue. Its offerings include amniotic membrane and umbilical cord allografts for use in wound care and surgical procedures. The company’s products include EpiFix, used in the management of certain chronic wounds, and other tissue-based products for wound and surgical applications. MiMedx uses its proprietary PURION processing method to prepare donated tissue for clinical use. Founded in 2008 and headquartered in Marietta, Georgia, MiMedx primarily serves healthcare providers in the United States, with sales in select international markets.
Featured Stories
- Five stocks we like better than MiMedx Group
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.
